DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages

Translate

Keratoacanthoma

Authors: Associate Professor Amanda Oakley, 1999; updated by Katrina Tan, Medical Student, Monash University, Melbourne, Australia; Dr Martin Keefe, Dermatologist, Christchurch, New Zealand. Copy edited by Gus Mitchell. November 2021.


Keratoacanthoma — codes and concepts
open

What is a keratoacanthoma?

Keratoacanthoma (KA) is a common, rapidly growing, locally destructive skin tumour.  KAs may regress spontaneously with scarring, but clinically they may be indistinguishable from well-differentiated squamous cell carcinoma (SCC) and the clinical course may be unpredictable. Thus, many clinicians and pathologists prefer the term SCC, KA-type and recommend surgical excision.

Keratoacanthoma

For more images, click here.

Who gets a keratoacanthoma?

Keratoacanthoma is most common in fair-skinned older males with a history of chronic sun exposure. Most patients are over 60 years of age and it is twice as common in males than in females. The incidence rate in Queensland, Australia is 409/100,000 person-years.

There is an increased incidence in:

What causes a keratoacanthoma?

Keratoacanthoma arises from the infundibulum of the hair follicle. The specific pathogenetic mechanisms are unclear but may involve aberrant regulation of the WNT signal transduction pathways and mutations in the tumour suppression gene TP53.

The risk factors are probably the same as for squamous cell carcinoma, and include:

  • Exposure to ultraviolet light
  • Chemical carcinogens (e.g. cigarette smoking, industrial workers exposed to tar, pitch, and mineral oils)
  • Cutaneous trauma (e.g. surgery, radiation)
  • Human papillomavirus infection.

What are the clinical features of a keratoacanthoma?

Keratoacanthomas typically present as a solitary, rapidly growing nodule on sun-exposed skin of the face and upper limbs. Keratoacanthomas are sharply demarcated, firm, erythematous or skin-coloured, with a classic central hyperkeratotic plug and an even shoulder. Removal of the keratotic core will leave a ‘crater’-like appearance to the lesion.

There are several variants and syndromes of keratoacanthoma:

  • Solitary keratoacanthoma (most common)
    • Single lesion, growing rapidly within a few weeks up to a diameter of 1–2 cm. After several weeks of stability, the lesion starts to spontaneously regress, eventually leaving a depressed scar. The time from first appearance to complete regression is usually 4–6 months.
  • Keratoacanthoma centrifugum marginatum
    • A rare variant of KA, characterised by peripheral expansion and central healing with scarring, often with no tendency to regression. Tumours may reach a diameter of 20 cm or more.
    • Diagnosis may be difficult and they may be confused with inflammatory dermatoses and other tumours.
  • Giant keratoacanthoma
    • Typically, a solitary KA grows larger than 2cm.
    • Commonly involves the eyelids or nose.
  • Multiple familial keratoacanthoma of Witten and Zak.
    • A rare, autosomal, dominantly-inherited variant of KA that presents in childhood with overlapping features of the Ferguson-Smith and Grzybowski subtypes.
    • It is characterised by multiple tiny papular lesions and larger, more typical KAs.

How do clinical features vary in differing types of skin?

Keratoacanthomas are much less common in patients with skin of colour, but the clinical features are the same.

What are the complications of keratoacanthoma?

The complications of keratoacanthoma include:

  • Scarring
  • Destruction of adjacent structures
  • Ulceration
  • Bleeding.

How is keratoacanthoma diagnosed?

Keratoacanthoma is diagnosed on the basis of a typical history, the clinical signs and histopathology.

The classic keratoacanthoma has a crateriform appearance when viewed histologically at low power. Higher power reveals enlarged atypical keratinocytes with eosinophilic cytoplasm that do not extend beyond the level of the sweat glands. These features may be impossible to see in partial or shave biopsy samples, which are not recommended.

Some otherwise typical KAs show squamous cells in a peripheral zone with atypical mitotic figures, hyperchromatic nuclei, and penetration into surrounding tissue. Such lesions are often reported as SCC, KA-type to reflect uncertainty about their true nature.

Unfortunately, dermoscopy cannot reliably discriminate KA from SCC.

What is the differential diagnosis for keratoacanthoma?

Keratoacanthomas must be distinguished from well-differentiated SCC. Other differential diagnoses include:

What is the treatment for keratoacanthoma?

Most keratoacanthomas are treated surgically. Although they may resolve spontaneously, it is usually prudent to excise them, unless there is clear evidence that regression is in progress.

It is usually best to assume a KA-like lesion is an SCC and to manage accordingly in line with local or national guidance, until proven otherwise.

In selected cases, experienced clinicians may consider other options, such as:

Samples for histology will be absent or may be imperfect, but the above techniques may be deemed suitable after considering the size and location of the tumour, the overall health of the patient and the likely morbidity from surgery.

What is the outcome for keratoacanthoma?

Keratoacanthoma is regarded as benign and thus has an excellent prognosis following surgical excision.

Lesions that progress and metastasise have probably been SCC, KA-type all along. Patients have an increased incidence of other sun-related skin cancers and should be advised about sun protection and self-examination

 

Bibliography

  • Gleich T, Chiticariu E, Huber M, Hohl D. Keratoacanthoma: a distinct entity? Exp Dermatol. 2016;25(2):85–91. doi:10.1111/exd.12880. PubMed
  • Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol. 2016;74(6):1220–33. doi:10.1016/j.jaad.2015.11.033. Journal
  • Misago N, Inoue T, Koba S, Narisawa Y. Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture: classification and identification. J Dermatol. 2013;40(6):443–52. doi:10.1111/1346-8138.12104. Journal
  • Savage JA, Maize JC, Sr. Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol. 2014;36(5):422–9. Journal
  • Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg. 2004;30(2 Pt 2):326–33. doi:10.1111/j.1524-4725.2004.30080.x. Journal
  • Tisack A, Fotouhi A, Fidai C, Friedman BJ, Ozog D, Veenstra J. A clinical and biological review of keratoacanthoma. Br J Dermatol. 2021;185(3):487–98. doi:10.1111/bjd.20389. Journal
  • Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007;46(7):671–8. doi:10.1111/j.1365-4632.2007.03260.x. Journal
  • Claeson M, Pandeya N, Dusingize J, et al. Assessment of Incidence Rate and Risk Factors for Keratoacanthoma Among Residents of Queensland, Australia. JAMA Dermatol. 2020;156(12):1324–32. doi:10.1001/jamadermatol.2020.4097. Journal

On DermNet NZ

Other websites

Books about skin diseases

Text: Miiskin

 

Related information

Sign up to the newsletter